Isabelle Mahé on Reduced Dose Apixaban and Cancer-Associated VTE
Isabelle Mahé, Head of Internal Medicine, Louis Mourier Hospital, APHP, Paris Cité University, shared on LinkedIn:
”Just published in the Lancet Haematology
In this post-hoc analysis of the API-CAT Study, including patients with CAT receiving extended anticoagulant with apixaban.
- 4 clinical predictors were significantly associated with increased CRB risk : anaemia and/or thrombocytopenia, age ≥75, PE as the index event, and male sex.
- 3 of them are also significant predictors of MB
- Identified predictors are non modifiable
- No cancer-related predictors associated with increased CRB risk
- Associations are consistent across cancer sites
- No evidence of interaction with apixaban dose
To reach the publication.
To reach the Comment.
As a reminder, in CAT extended treatment NEJM
Reduced dose apixaban is non inferior to full-dose on VTE recurrence, and associated with a 25% reduction in the risk of CRB
To reach the publication: Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism. DOI 10.1056/NEJMoa2416112”
Read the full article here.
Article: Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism
Authors: Isabelle Mahé, Marc Carrier, Didier Mayeur, Jean Chidiac, Eric Vicaut, Nicolas Falvo, Olivier Sanchez et al.
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 25, 2026, 18:36James P. Crowley: Gene Inactivation and Targeted Gene Repair as Two Approaches to CRISPR Gene Editing
-
Oct 25, 2026, 17:43Jan Sloves: Femoral Vein Aneurysm and Chronic Venous Obstruction
-
Oct 25, 2026, 17:31Kasimu Hussaini: Blood Component Therapy From Whole Blood to Targeted Treatment
-
Oct 25, 2026, 17:23Zahra Safarzadeh: When Low Factor VII Activity and Reduced VWF Antigen Coexist
-
Oct 25, 2026, 17:17Anubhav Joshi: Evans Syndrome in CLL A Differential Diagnosis to Remember
-
Oct 25, 2026, 17:04Tehila Alter: Tracking Hematopoietic Cell Engraftment in Bone Marrow Using CEST MRI
-
Oct 25, 2026, 16:45Shauna Riley։ First Guidelines for Hemoglobin SC Disease
-
Oct 25, 2026, 16:26Heghine Khachatryan: Patient Safety and Clinical Judgment in Platelet Transfusion Decisions
-
Oct 25, 2026, 16:13Funmi (Vanessa) Ullam: From Lived Experience to Research and Innovation in Sickle Cell Care